Related Experiment Video

Updated: Jun 24, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

[Advances in neoadjuvant therapy for EGFR-mutant non-small cell lung cancer]

Y Q Wu1, R B Zhong1

  • 1Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|June 22, 2026
PubMed

Insights

Neoadjuvant EGFR-tyrosine kinase inhibitors (TKIs) are revolutionizing treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. Osimertinib-based therapies show promise in preventing recurrence after surgery.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Epidermal growth factor receptor (EGFR) mutations are prevalent in non-small cell lung cancer (NSCLC), particularly in Asian populations.
  • High recurrence rates post-surgery for resectable EGFR-mutant NSCLC present a significant clinical challenge.
  • Neoadjuvant therapy has evolved from chemotherapy to targeted EGFR-tyrosine kinase inhibitors (TKIs) to improve outcomes.

Purpose of the Study:

  • To systematically review the evolution and recent advancements in neoadjuvant therapy for EGFR-mutant NSCLC.
  • To highlight the role of precision therapies in the neoadjuvant setting.
  • To discuss future directions in treatment strategies.

Main Methods:

  • Systematic literature review of neoadjuvant therapies for EGFR-mutant NSCLC.
  • Analysis of clinical trial data and evidence-based medicine regarding TKI efficacy.
  • Evaluation of current and emerging treatment paradigms.

Main Results:

  • Osimertinib-based regimens (monotherapy or combination) are emerging as promising neoadjuvant options for EGFR-mutant NSCLC.
  • These regimens are supported by high-level evidence and aim to improve surgical outcomes and survival.
  • Immunotherapy shows limitations in this specific patient population.

Conclusions:

  • Neoadjuvant osimertinib-based therapies represent a significant advancement for EGFR-mutant NSCLC.
  • Future strategies will likely focus on combination therapies and biomarker-guided individualized treatment.
  • Personalized medicine is the future direction for managing EGFR-mutant NSCLC.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...